BioDeutschland: Findings of the survey of companies 2011/2012


Despite a more positive assessment of their current situation, German biotech companies are starting 2012 less optimistically. By using product and service models, the sector is making itself ever less dependent on venture capital. This was found in a survey conducted by BIO Deutschland in cooperation with the sector journal, |transkript. The findings of this barometer of the sector were presented at a press conference in Berlin on 16 January 2012.

Early indicators show that a constantly growing number of employees accompanied by slightly decreasing expenditure on R&D can be expected. At the same time, expectations of the future business situation are declining. As the biotechnology news journal |transkript also established, around 141 million euro of new capital went to German biotechnology companies in 2011. (2010: 650 million euro).